Launching this month exclusively in Fleur Marche, Australia's HEMPLE is bringing its nano-CBD high spectrum hemp extract Stigma to the United States.
“We’re establishing Hemple as a brand known for high quality, effective and innovative cannabinoid wellness products," co-founder Georgia Branch told Benzinga. "That means combining market-leading technology like nano emulsification with functional combinations of cannabinoids - from CBD to CBG and beyond - with other plant based botanicals.”
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
Branch says HEMPLE is excited to partner with Fleur Marche.
"Our businesses share a focus on quality and transparency, a commitment to every product displaying 3rd party lab testing, an open dialogue with customers as well as ongoing education," he said.
According to Branch, the plan is to expand the range of ingestible products and introduce topicals over the coming months.
Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!